S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

3 Tempting Selloffs: Are They Tricks or Treats?

Friday, October 22, 2021 | MarketBeat Staff
3 Tempting Selloffs: Are They Tricks or Treats?

When a stock sells off, i.e., suffers a sustained downtrend, it can be for good reason. A negative press release or unfavorable industry dynamics are just two examples.

Other times the selloff can be overdone. This commonly occurs when market participants overreact to negative near-term news and lose sight of a company’s longer-term opportunities.

While the major indices have rallied back towards record highs, not all stocks have joined the party. In fact, over the past month, a bunch of stocks has endured major downturns of 20%, 30%, or more. This presents the question of whether or not to buy the dip in such stocks.

Like a pillowcase full of undesirable Halloween candy, you never want to be caught holding a bad bag. Conversely, you hate to miss out on great buy opportunities. Let’s look at whether these three dips are tricks or treats.

Will Novavax Stock Recover?

Novavax (NASDAQ: NVAX) shares are down approximately 40% over the past month. On Wednesday, the biotech gapped lower in heavy volume on reports that its COVID-19 vaccine is facing production delays. Not the first time the company has had problems with getting its vaccine off the ground, the most recent hurdle relates to an inability to meet the quality standards of U.S. regulators.

Despite the bad headline, management tried to assure the market that it will still be able to make its vaccine and adhere to regulatory filing deadlines. The reassurances have mostly fallen on deaf ears.

There is at least one Wall Street analyst who thinks this has created a buy opportunity. Cantor Fitzgerald reiterated its overweight rating and $272 price target on Novavax which points to a potential two-bagger. The firm asserted that Novavax is wrapping up its regulatory filings that once submitted they “will dissipate the debate of vaccine quality”.

Novavax’s COVID-19 vaccine is clearly its biggest growth driver and much hinges on the success of this product. It is important to keep in mind though that its NanoFlu vaccine and pipeline of other infectious disease product candidates also hold great promise for the long-term.

Trick or Treat? Treat

 Is Bed Bath & Beyond Stock a Buy?

Bed Bath & Beyond (NASDAQ: BBBY) is trading near a 52-week low after suffering a crippling blow late last month. The retailer missed badly on second-quarter earnings as consumer traffic unexpectedly slowed late in the period. This prompted management to lower its full-year outlook accelerating the stock’s descent.

The question with Bed Bath & Beyond is whether these challenges are temporary or the start of a sustained downtrend. On the plus side, the slowdown was tied to rising delta variant cases particularly in key states like California, Florida, and Texas. So, with caseloads gradually improving nationwide and the holiday shopping season ahead, customer traffic is bound to pick up.

On the negative side, Bed Bath & Beyond still has a lot of work to do to catch up with competitors who have done a better job of enhancing their merchandise assortments and online storefronts to meet the demands of modern consumers. Cost and debt pressures also continue to weigh.

Moreover, the elephant in the bedroom is that Bed Bath & Beyond appears to be losing relevance in the retail world. Shoppers are flocking to Amazon and other e-commerce outlets like never before. And although Bed Bath & Beyond’s digital capabilities are improving, it will be difficult to gain ground in this consumer environment while playing from behind.

Of course, as a popular meme stock, there is always the possibility of another social media-fueled rally. Barring this, however, investors are better-served shopping elsewhere.

Trick or Treat? Trick

Is it a Good Time to Buy WalkMe Stock?

After climbing above $34 last month, recent IPO WalkMe (NASDAQ: WKME) has seen $10 shed from its share price. The provider of software that supports digital transformations hasn’t had any major developments to prompt the decline which is good news for investors.

WalkMe’s cloud-based Digital Adoption Platform has the potential to change the way consumers and employees conduct business online. It has already amassed nearly 1 billion users which represents a solid foundation for recuring subscription revenue growth.  And with organizations of all shapes and sizes just starting to embrace digital adoption software to improve user experiences, the growth runway is long in this $34 billion market. Research firm Gartner estimated that by 2025, 70% of organizations will use solutions such as those offered by WalkMe.

During the stock’s recent slide two sell-side firms have called WalkMe a ‘buy’. Their $40 and $42 target prices suggest at least 60% upside. The company is gaining traction in a nascent but fast-growing software niche that will be an important part of the digital transformation for years to come. The current $2 billion valuation is reasonable if not inexpensive and the stock’s recent bounce off a double bottom is bullish.

Trick or Treat? Treat

Should you invest $1,000 in Bed Bath & Beyond right now?

Before you consider Bed Bath & Beyond, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bed Bath & Beyond wasn't on the list.

While Bed Bath & Beyond currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Bed Bath & Beyond (BBBY)2.4$20.90-6.2%N/A-12.08Hold$21.55
Novavax (NVAX)1.9$217.97+8.9%N/A-14.72Buy$249.60
WalkMe (WKME)2.0$20.41-1.4%N/AN/ABuy$39.71
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.